365 related articles for article (PubMed ID: 28065582)
1. Bivalent flagellin immunotherapy protects mice against Pseudomonas aeruginosa infections in both acute pneumonia and burn wound models.
Ahmadi H; Behrouz B; Irajian G; Amirmozafari N; Naghavi S
Biologicals; 2017 Mar; 46():29-37. PubMed ID: 28065582
[TBL] [Abstract][Full Text] [Related]
2. Antibodies raised against divalent type b flagellin and pilin provide effective immunotherapy against Pseudomonas aeruginosa infection of mice with burn wounds.
Saffari M; Behbood S; Irajian G; Khorshidi A; Moniri R; Behrouz B
Biologicals; 2017 Jan; 45():20-26. PubMed ID: 27836582
[TBL] [Abstract][Full Text] [Related]
3. Anti-flagellin IgY antibodies protect against Pseudomonas aeruginosa infection in both acute pneumonia and burn wound murine models in a non-type-specific mode.
Ahmadi TS; Mousavi Gargari SL; Talei D
Mol Immunol; 2021 Aug; 136():118-127. PubMed ID: 34130152
[TBL] [Abstract][Full Text] [Related]
4. Flagellin and pilin immunization against multi-drug resistant Pseudomonas aeruginosa protects mice in the burn wound sepsis model.
Korpi F; Hashemi FB; Irajian G; Fatemi MJ; Laghaei P; Behrouz B
Immunol Lett; 2016 Aug; 176():8-17. PubMed ID: 27210422
[TBL] [Abstract][Full Text] [Related]
5. Protective efficacy of Pseudomonas aeruginosa type-A flagellin in the murine burn wound model of infection.
Faezi S; Safarloo M; Amirmozafari N; Nikokar I; Siadat SD; Holder IA; Mahdavi M
APMIS; 2014 Feb; 122(2):115-27. PubMed ID: 23758581
[TBL] [Abstract][Full Text] [Related]
6. Anti-PcrV IgY antibodies protect against Pseudomonas aeruginosa infection in both acute pneumonia and burn wound models.
Ranjbar M; Behrouz B; Norouzi F; Mousavi Gargari SL
Mol Immunol; 2019 Dec; 116():98-105. PubMed ID: 31634816
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of antibodies against the N-terminal of Pseudomonas aeruginosa flagellin for treating infections in a murine burn wound model.
Barnea Y; Carmeli Y; Gur E; Kuzmenko B; Gat A; Neville LF; Eren R; Dagan S; Navon-Venezia S
Plast Reconstr Surg; 2006 Jun; 117(7):2284-91. PubMed ID: 16772930
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of the immune responses following co-administration of PilQ and type b-flagellin from Pseudomonas aeruginosa in the burn mouse model.
Bakht Azad S; Nikokar I; Faezi S; Rasooly S; Mahdavi M
Microb Pathog; 2018 Oct; 123():426-432. PubMed ID: 30075242
[TBL] [Abstract][Full Text] [Related]
9. Immunization with Bivalent Flagellin Protects Mice against Fatal
Behrouz B; Hashemi FB; Fatemi MJ; Naghavi S; Irajian G; Halabian R; Imani Fooladi AA
J Immunol Res; 2017; 2017():5689709. PubMed ID: 29201922
[No Abstract] [Full Text] [Related]
10. Passive immunisation against Pseudomonas aeruginosa recombinant flagellin in an experimental model of burn wound sepsis.
Faezi S; Sattari M; Mahdavi M; Roudkenar MH
Burns; 2011 Aug; 37(5):865-72. PubMed ID: 21334822
[TBL] [Abstract][Full Text] [Related]
11. Immunization with outer membrane proteins (OprF and OprI) and flagellin B protects mice from pulmonary infection with mucoid and nonmucoid Pseudomonas aeruginosa.
Hassan R; El-Naggar W; Abd El-Aziz AM; Shaaban M; Kenawy HI; Ali YM
J Microbiol Immunol Infect; 2018 Jun; 51(3):312-320. PubMed ID: 28291719
[TBL] [Abstract][Full Text] [Related]
12. Antibodies raised against N'-terminal Pseudomonas aeruginosa flagellin prevent mortality in lethal murine models of infection.
Neville LF; Barnea Y; Hammer-Munz O; Gur E; Kuzmenko B; Kahel-Raifer H; Eren R; Elkeles A; Murthy KG; Szabó C; Salzman AL; Dagan S; Carmeli Y; Navon-Venezia S
Int J Mol Med; 2005 Jul; 16(1):165-71. PubMed ID: 15942694
[TBL] [Abstract][Full Text] [Related]
13. Immunogenicity and protective efficacy of Pseudomonas aeruginosa type a and b flagellin vaccines in a burned mouse model.
Laghaei P; Hashemi FB; Irajian G; Korpi F; Amirmozafari N; Behrouz B
Mol Immunol; 2016 Jun; 74():71-81. PubMed ID: 27152476
[TBL] [Abstract][Full Text] [Related]
14. A trivalent vaccine consisting of "flagellin A+B and pilin" protects against Pseudomonas aeruginosa infection in a murine burn model.
Hashemi FB; Behrouz B; Irajian G; Laghaei P; Korpi F; Fatemi MJ
Microb Pathog; 2020 Jan; 138():103697. PubMed ID: 31465785
[TBL] [Abstract][Full Text] [Related]
15. Immunization of young African green monkeys with OprF epitope 8-OprI-type A- and B-flagellin fusion proteins promotes the production of protective antibodies against nonmucoid Pseudomonas aeruginosa.
Weimer ET; Ervin SE; Wozniak DJ; Mizel SB
Vaccine; 2009 Nov; 27(48):6762-9. PubMed ID: 19744586
[TBL] [Abstract][Full Text] [Related]
16. Divalent flagellin immunotherapy provides homologous and heterologous protection in experimental urinary tract infections in mice.
Sabharwal N; Chhibber S; Harjai K
Int J Med Microbiol; 2016 Jan; 306(1):29-37. PubMed ID: 26655680
[TBL] [Abstract][Full Text] [Related]
17. Therapy with anti-flagellin A monoclonal antibody limits Pseudomonas aeruginosa invasiveness in a mouse burn wound sepsis model.
Barnea Y; Carmeli Y; Neville LF; Kahel-Reifer H; Eren R; Dagan S; Navon-Venezia S
Burns; 2009 May; 35(3):390-6. PubMed ID: 18951715
[TBL] [Abstract][Full Text] [Related]
18. Protective Efficacy of the Trivalent Pseudomonas aeruginosa Vaccine Candidate PcrV-OprI-Hcp1 in Murine Pneumonia and Burn Models.
Yang F; Gu J; Yang L; Gao C; Jing H; Wang Y; Zeng H; Zou Q; Lv F; Zhang J
Sci Rep; 2017 Jun; 7(1):3957. PubMed ID: 28638106
[TBL] [Abstract][Full Text] [Related]
19. Protective efficacy of recombinant exotoxin A--flagellin fusion protein against Pseudomonas aeruginosa infection.
Farajnia S; Peerayeh SN; Tanomand A; Majidi J; Goudarzi G; Naghili B; Rahbarnia L
Can J Microbiol; 2015 Jan; 61(1):60-4. PubMed ID: 25496361
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of flagella and flagellin of Pseudomonas aeruginosa as vaccines.
Campodónico VL; Llosa NJ; Grout M; Döring G; Maira-Litrán T; Pier GB
Infect Immun; 2010 Feb; 78(2):746-55. PubMed ID: 19995892
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]